Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1

Tim R. Cressey, Gonzague Jourdain, Marc J. Lallemant, Suparat Kunkeaw, J. Brooks Jackson, Philippa Musoke, Edmund Capparelli, Mark Mirochnick

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To determine nevirapine (NVP) plasma levels during the postpartum period after a single intrapartum NVP dose for the prevention of mother-to-child transmission. Methods: Plasma samples at delivery and during days 8 to 45 postpartum were obtained from HIV-infected Thai women who received an intrapartum NVP dose in the Perinatal HIV Prevention Clinical Trial-2 (PHPT-2) for the prevention of perinatal HIV transmission. These data were combined with NVP concentration data from 2 phase 1 studies of NVP for a population analysis. Results: The median NVP level fell to 68 ng/mL (range:

Original languageEnglish (US)
Pages (from-to)283-288
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume38
Issue number3
StatePublished - Mar 1 2005

Keywords

  • Nevirapine
  • Pharmacokinetics
  • Prevention mother-to-child HIV transmission

ASJC Scopus subject areas

  • Virology
  • Immunology

Fingerprint

Dive into the research topics of 'Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1'. Together they form a unique fingerprint.

Cite this